Triple

T22404705
Position Surface form Disambiguated ID Type / Status
Subject PRAC E553849 entity
Predicate regulatoryFramework P1051 FINISHED
Object Directive 2001/83/EC as amended by pharmacovigilance legislation NE NERFINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Directive 2001/83/EC as amended by pharmacovigilance legislation | Statement: [PRAC, regulatoryFramework, Directive 2001/83/EC as amended by pharmacovigilance legislation]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Directive 2001/83/EC as amended by pharmacovigilance legislation
Context triple: [PRAC, regulatoryFramework, Directive 2001/83/EC as amended by pharmacovigilance legislation]
  • A. Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
    The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
  • B. European Union pharmaceutical legislation chosen
    European Union pharmaceutical legislation is the body of EU laws and regulations that governs the authorization, supervision, safety, and quality of medicines for human and veterinary use across member states.
  • C. Conditional Marketing Authorization by European Medicines Agency
    Conditional Marketing Authorization by the European Medicines Agency is a fast-track regulatory pathway that allows earlier approval of medicines, such as COVID-19 vaccines, based on less comprehensive data than normally required, provided that the benefits outweigh the risks and additional data will be supplied post-approval.
  • D. WHO Collaborating Centre for Drug Statistics Methodology
    The WHO Collaborating Centre for Drug Statistics Methodology is a specialized World Health Organization center responsible for developing and maintaining international standards for drug classification and consumption statistics, including the ATC/DDD system.
  • E. Certificates of Suitability to the monographs of the European Pharmacopoeia
    Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e11e4da7048190b4387d422a9a0de5 completed April 16, 2026, 5:37 p.m.
NER Named-entity recognition batch_69f158b739b88190a7f1f20fd1e9b188 completed April 29, 2026, 1:02 a.m.
Created at: April 16, 2026, 8:46 p.m.